Imaging Biomarkers in Lung Cancer with $^{68}$Ga-DOTATATE, $^{18}$F-Fluoride, and $^{18}$F-FDG PET/CT Scans and the Theranostics Paradigm

Mehdi Djekidel$^1$, Ghulam Syed$^2$, and Aladdin Kanbour$^3$

1NCCCR, Division of Oncology, Hamad Medical Corporation, Doha, Qatar; 2Department of Radiology, Division of Nuclear Medicine, Hamad Medical Corporation, Doha, Qatar; and 3Department of Radiology, Division of Nuclear Medicine, Sidra Medicine, Doha, Qatar

Lung cancer is the number 1 cause of cancer deaths in the United States. The overall 5-y survival is 12% (1). The adenocarcinoma subtype is the most common primary lung cancer. The prognosis is quite grim with the exception of stage 1. When faced with several failed therapeutic regimens and rapid progression of the disease, exploring alternative therapies such as radiopharmaceutical therapies may be an option. We describe the case of a 36-y-old man with lung adenocarcinoma who had imaging molecular characterization of his disease with $^{18}$F-FDG, $^{68}$Ga-DOTATATE, and $^{18}$F-fluoride PET/CT scans that were able to shed some light on molecular characterization of his disease and serve as a guide to potential targeted or personalized radiopharmaceutical therapeutic options.

Key Words: lung cancer; lung adenocarcinoma; $^{18}$F-FDG; $^{68}$Ga-DOTATATE; $^{18}$F-fluoride; theranostics

DOI: 10.2967/jnmt.120.258343

Lung cancer is the number 1 cause of cancer deaths in the United States. The overall 5-y survival is 12% (1). The adenocarcinoma subtype is the most common primary lung cancer. The prognosis is quite grim with the exception of stage 1 (1,2). Somatostatin receptor expression has been described in lung cancer in general and also specifically in lung adenocarcinomas (3–6). Today, $\beta$- and $\alpha$-emitters are available for treatment clinically. The Food and Drug Administration and the European Medicines Agency have approved $^{177}$Lu-DOTATATE and $^{223}$Ra for the treatment of gastroenteropancreatic neuroendocrine tumors and metastatic castration-resistant prostate cancers, respectively. However, these agents have also been used off-label, such as in neuroblastoma, pheochromocytoma, paraganglioma, and thyroid cancer patients. When faced with several failed therapeutic regimens and rapid progression of the disease, exploring alternative therapies such as radiopharmaceutical therapies may be an option. In a theranostic approach, the choice of the radiopharmaceutical used for treatment is important and will depend on the distribution of the disease and on uptake of the specific companion diagnostic agent.

CASE REPORT

We present the case of a 36-y-old man who quickly progressed to advanced, stage IV, moderately differentiated lung adenocarcinoma with metastasis to the liver and bone. Initial staging CT scans on May 12, 2019, showed an irregular right-upper-lobe mass and a few small sub-centimeter mediastinal lymph nodes. Biopsy revealed a moderately differentiated lung adenocarcinoma that was anaplastic large cell lymphoma–negative, had PD-L1 expression in 35% of the tumor, and had a next-generation sequencing EGFR mutation in exon 20 and a JAK mutation in exon 14. The initial staging $^{18}$F-FDG scan showed uptake in the primary right-upper-lobe lesion and mediastinal lymph nodes, with no distant metastases (Fig. 1). Brain MRI findings were unremarkable. Right upper lobectomy and mediastinal lymph node dissection were performed, revealing invasive adenocarcinoma, mainly of the acinar subtype, and micropapillary components; there was a grade 1, well-differentiated single tumor measuring $4.2 \times 2.8 \times 2.5$ cm (R0). Spread of the tumor through air spaces was present. Visceral pleural invasion was also present, as well as extensive lymphovascular invasion. Twelve of 16 regional lymph nodes were involved, with extranodal extension. The patient at initial surgery had stage IIIA disease (T2b N2 M0). Surgery was followed by 4 cycles of adjuvant cisplatin/vinorelbine tartrate and adjuvant radiotherapy. About 1 mo after completion of adjuvant chemoradiation, the patient presented with generalized bone pain, and an $^{18}$F-fluoride PET scan showed widespread bony metastasis (Fig. 2). This rapid progression of disease required an inpatient hospital stay and several narcotics for pain control. These findings prompted consideration of palliation with radionuclide-based treatments and bone-seeking agents such as $^{153}$Sm, $^{89}$Sr, $^{186}$Re, $^{188}$Re, or even $^{223}$Ra. However, bearing in mind that the patient might also have additional soft-tissue disease, a $^{68}$Ga-DOTATATE scan was performed to assess whether the disease was predominantly in the bones or also in the soft tissues (Fig. 3). This scan showed mostly bony lesions, slightly...
less prominent than on the $^{18}$F-fluoride scan, and minimal uptake in the pleura, best appreciated retrospectively. Restaging $^{18}$F-FDG PET done within a few days showed not only bony disease but also right-sided pleural disease and fewer than 5 subcentimeter liver deposits, also not appreciated on the $^{68}$Ga-DOTATATE scan (Fig. 4). The progression of disease and molecular characterization are summarized in Figure 5.  

**DISCUSSION**

$^{223}$Ra, an α-emitter selectively targeting bone metastasis, improved overall survival in the ALSYMPCA trial in castration-resistant metastatic prostate cancer ($7,8$). $^{177}$Lu-DOTATATE, a β-emitter, also improved overall survival, progression-free survival, and quality of life in patients with midgut neuroendocrine tumors from the NETTER-1 study ($9$). Although radiopharmaceutical therapies are seldom used in lung cancer, there is a growing interest in use in a variety of cancers. $^{177}$Lu-DOTATATE–based radiopharmaceutical therapies were also shown to improve overall and progression-free survival in bronchopulmonary carcinoids ($10–13$). Reports have also discussed the $^{177}$Lu-DOTATATE treatment paradigm in small cell lung cancer ($14–17$). Additionally, some reports and clinical trials are evaluating the benefit of $^{223}$Ra in non–small cell lung cancer ($18–20$). One of the prerequisites for $^{177}$Lu treatment is somatostatin receptor expression demonstrated on a companion diagnostic $^{177}$Lu-DOTATATE PET scan such as in our case. Positive bone scan results are the companion diagnostic for $^{223}$Ra. $^{18}$F-fluoride and $^{177}$Lu-DOTATATE PET scans offer a road map to assess the eligibility of a patient for a therapeutic option. This, of course, is currently limited to situations in which all conventional treatments have been exhausted. In our patient, we considered palliative treatment with radiopharmaceutical therapies with bone-seeking agents such as $^{153}$Sm, $^{89}$Sr, or even $^{223}$Ra. $^{177}$Lu-DOTATATE treatment was considered within a theranostic approach in the context of the patient’s also having some soft-tissue disease in the pleura and liver. Bone-seeking radiopharmaceuticals may be preferred in bone-predominant disease, and $^{177}$Lu-DOTATATE–based therapeutic radiopharmaceuticals may be preferred for non–bone-predominant disease. After declining any additional chemotherapy or immunotherapy and complete molecular characterization of the patient’s disease with PET, the patient then traveled to his home country and passed away shortly thereafter.

**CONCLUSION**

Considering that lung cancer patients frequently have a poor prognosis, radiopharmaceutical therapies should be kept in mind even if only for palliation of disease. In the era of theranostics, it becomes feasible to assess targets by pretherapy imaging such as, in our patient, with $^{18}$F-fluoride and $^{68}$Ga-DOTATATE. Further studies and clinical trials are needed for validation in lung cancer and other types of cancer.
and liver disease.

months later, $^{18}$F-fluoride in Figure 2. Liver and pleural involvement seen on subsequent $^{18}$F-FDG scan 1 wk later is not clearly appreciated with $^{68}$Ga-DOTATATE. From right to left maximum-intensity-projection PET, coronal PET/CT, and coronal PET/CT images.

$^{68}$Ga-DOTATATE PET/CT scan. Diffuse bony metastasis is noted; uptake of $^{68}$Ga-DOTATATE is less prominent than that of $^{18}$F-fluoride in Figure 2. Liver and pleural involvement seen on subsequent $^{18}$F-FDG scan 1 wk later shows bony lesions less prominently than on $^{18}$F-fluoride scan, somewhat similar to follow-up $^{18}$F-FDG PET/CT scan. (D) Follow-up $^{18}$F-FDG PET/CT scan 1 wk later shows bony lesions and pleural and liver disease.

$^{18}$F-FDG scan shows diffuse bony lesions but also detecting pleural and very minimal subtle liver disease not visualized on $^{68}$Ga-DOTATATE scan. From right to left maximum-intensity-projection PET, coronal PET, sagittal PET/CT, and coronal PET/CT images.

$^{18}$F-FDG PET/CT IN LUNG CANCER

No potential conflict of interest relevant to this article was reported.

REFERENCES


